Promotion of hematopoiesis

Promotion of hematopoiesis is a complex physiological process involving the production of all cellular components of blood from pluripotent hematopoietic stem cells (HSCs) (StatPearls, 2023). It is not a single molecular target but rather a therapeutic objective achieved by modulating various specific receptors, such as the Erythropoietin receptor (EPOR) for red blood cells, the Thrombopoietin receptor (MPL) for platelets, and the Granulocyte colony-stimulating factor receptor (G-CSFR) for neutrophils (NIH, 2022). Activation of these receptors typically triggers intracellular signaling cascades, most notably the JAK-STAT pathway, which drives the proliferation and maturation of lineage-specific progenitor cells (PubMed, PMID: 30248019). Clinically, pharmacological agents are used to promote hematopoiesis in patients suffering from cytopenias caused by myelosuppressive chemotherapy, chronic kidney disease, or primary bone marrow disorders (FDA, 2021). While effective, the therapeutic overstimulation of these pathways carries significant safety risks, including increased blood viscosity leading to thrombosis, splenic rupture, and potential stimulation of malignant cell growth in certain cancers (Journal of Clinical Oncology, 2019).

Other names

Hematopoietic stimulationBlood cell productionHemopoiesisHematopoietic induction

Agonism of lineage-specific hematopoietic growth factor receptors (e.g., EPOR, G-CSFR, MPL) to activate the JAK-STAT signaling pathway and induce cellular proliferation and differentiation.